Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine

PHASE4TerminatedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

December 4, 2019

Primary Completion Date

July 28, 2021

Study Completion Date

July 28, 2021

Conditions
Migraine
Interventions
DRUG

Placebo

Placebo once every 4 weeks. SC injection.

DRUG

Erenumab

Erenumab once every 4 weeks. SC injection.

Trial Locations (28)

19107

Research Site, Philadelphia

21742

Research Site, Hagerstown

27405

Research Site, Greensboro

27713

Research Site, Durham

32216

Research Site, Jacksonville

32806

Research Site, Orlando

35235

Research Site, Birmingham

35805

Research Site, Huntsville

37203

Research Site, Nashville

45459

Research Site, Centerville

48104

Research Site, Ann Arbor

55402

Research Site, Minneapolis

63141

Research Site, St Louis

63303

Research Site, City of Saint Peters

65613

Research Site, Bolivar

65810

Research Site, Springfield

70043

Research Site, Chalmette

75034

Research Site, Frisco

78731

Research Site, Austin

81621

Research Site, Basalt

84109

Research Site, Salt Lake City

90094

Research Site, Los Angeles

91105

Research Site, Pasadena

06118

Research Site, East Hartford

06320

Research Site, New London

06905

Research Site, Stamford

01605

Research Site, Worcester

08755

Research Site, Toms River

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Amgen

INDUSTRY

NCT03912337 - Effect of Erenumab-aooe on Disability and Work Productivity in Employed Subjects With Episodic Migraine | Biotech Hunter | Biotech Hunter